Skip to main content
. 2020 Aug 6;11:3929. doi: 10.1038/s41467-020-17577-8

Fig. 8. AAV-hSPB improves survival in neonatal and adult mice.

Fig. 8

a Kaplan-Meier survival curves following IT delivery of 5 × 1010 vg per mouse (dashed pink line; **P = 0.0019) of AAV-hSPB plus BLES with dox removal 28 days after AAV administration, and IT delivery of 1011 vg per mouse (solid pink line; ****P < 0.0001) of AAV-hSPB plus BLES with dox removal 7 days (D7) after AAV administration. b Mean weight measurements with SD of all surviving mice either treated with 1× PBS (blue squares) or 1011 vg of AAV-hSPB plus BLES (pink triangles) from a. c Study design to assess survival following IT delivery of 1011 vg per mouse AAV-hSPB plus BLES gene therapy in postnatal (P)8 to P10 SP-B deficient mice. Mice were removed from dox upon weaning at P21. d Kaplan-Meier survival curves following IT delivery of 1011 vg per mouse of AAV-hSPB plus BLES (pink line; ***P = 0.0004) at P8 to P10 with dox removal at P21. Control mice were untreated and maintained on dox (black line; **P = 0.0021) or underwent sham surgeries with IT injections of 1× PBS plus BLES (blue line). e Mean weight measurements with SD of all surviving mice untreated and maintained on dox (black circles), treated with 1× PBS plus BLES with dox removed (blue squares), or treated with 1011 vg of AAV-hSPB plus BLES with dox removed (pink triangles) from d. (Survival curve P values of a = 2-tailed Log-rank, Mantel-Cox test; Survival curve P values of d = 2-tailed Log-rank, Mantel-Cox test with Bonferroni correction, significance is set at P = 0.0167, ns = not significant) (BLES = Bovine Lipid Extract Surfactant).